Company Overview

Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.

  • Name

    Pro Medicus Limited

  • CEO

    Dr. Sam Aaron Hupert M.B.B.S., M.D.

  • Website

    www.promed.com.au

  • Sector

    Health Care Technology

  • Year Founded

    1983

Profile

  • Market Cap

    A$17.91B

  • EV

    A$17.75B

  • Shares Out

    104.5M

  • Revenue

    A$161.5M

  • Employees

Margins

  • Gross

    99.81%

  • EBITDA

    70%

  • Operating

    69.84%

  • Pre-Tax

    72.13%

  • Net

    51.27%

  • FCF

    50.57%

Returns (5Yr Avg)

  • ROA

    29.65%

  • ROTA

    60.01%

  • ROE

    45.07%

  • ROCE

    46.92%

  • ROIC

    65.27%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    A$128.25

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    A$155.43M

  • Net Debt

    -A$153.36M

  • Debt/Equity

    0.01

  • EBIT/Interest

Growth (CAGR)

  • Rev 3Yr

    33.38%

  • Rev 5Yr

    26.37%

  • Rev 10Yr

    27.46%

  • Dil EPS 3Yr

    38.93%

  • Dil EPS 5Yr

    34.01%

  • Dil EPS 10Yr

    48.67%

  • Rev Fwd 2Yr

    25.99%

  • EBITDA Fwd 2Yr

    28.43%

  • EPS Fwd 2Yr

    31.13%

  • EPS LT Growth Est

    35.88%

Dividends

  • Yield

  • Payout

    50.46%

  • DPS

    A$0.4

  • DPS Growth 3Yr

    38.67%

  • DPS Growth 5Yr

    37.97%

  • DPS Growth 10Yr

    34.93%

  • DPS Growth Fwd 2Yr

    32.86%

ASX:PME